Mark Haygood, DO
Psychiatry · Mobile, ALNPI 1073834370
Payments from drug & device makers
Across 1,322 payments — averaging $263.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$171K
- Neurocrine Biosciences, Inc.$149K
- Otsuka America Pharmaceutical, Inc.$18K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$844
- plus $6K from 26 others
What the payments were for
- Consulting fees$24,1937%
- Speaking & faculty fees$282,90981%
- Travel & lodging$18,7435%
- Food & beverage$22,1216%
- Education$2710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 599 | $171,329 |
| Neurocrine Biosciences, Inc. | 195 | $149,486 |
| Otsuka America Pharmaceutical, Inc. | 130 | $17,949 |
| Teva Pharmaceuticals USA, Inc. | 60 | $2,049 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $1,058 |
| Axsome Therapeutics, Inc. | 30 | $844 |
| Johnson & Johnson | 29 | $820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $621 |
| Vanda Pharmaceuticals Inc. | 37 | $619 |
| Supernus Pharmaceuticals, Inc. | 22 | $580 |
| E.r. Squibb & Sons, L.L.C. | 27 | $496 |
| Neuronetics, Inc. | 7 | $397 |
| Lundbeck LLC | 18 | $326 |
| Sunovion Pharmaceuticals Inc. | 3 | $242 |
| Abbott | 8 | $165 |
| Alkermes, Inc. | 9 | $165 |
| Stryker | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 7 | $118 |
| Adlon Therapeutics L.p. | 7 | $117 |
| Shire North American Group Inc | 10 | $111 |
| Corium, LLC | 8 | $110 |
| Eisai Inc. | 5 | $85 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $81 |
| OWP Pharmaceuticals, Inc. | 3 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Bausch Health US, LLC | 2 | $46 |
| Neos Therapeutics, LP | 2 | $43 |
| Tris Pharma Inc | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Alfasigma USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$163,978
- INGREZZA$146,125
- REXULTI$13,583
- ABILIFY MYCITE$2,430
- Austedo XR$655
- AUSTEDO$492
- CAPLYTA$376
- COBENFY$250
- Auvelity$249
- QELBREE$242
- SPRAVATO$233
- NEUROSTAR TMS THERAPY SYSTEM$224
- ENTELLUS - XPRESS ENT DILATION SYSTEM$150
- LATUDA$123
- NEUROSTAR TMS THERAPY$119
- TRINTELLIX$113
How this compares
$348,236 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $218,198 |
| RexultiBrexpiprazole | 17 | $33,352 |
| TrintellixVortioxetine Hydrobromide | 25 | $21,463 |
| Aripiprazole | 19 | $7,449 |
| Lurasidone Hcl | 31 | $6,544 |
| Vilazodone Hcl | 36 | $6,292 |
| Lisdexamfetamine Dimesylate | 22 | $3,627 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $2,005 |
| Bupropion XlBupropion Hcl | 69 | $1,709 |
| Lamotrigine | 126 | $1,527 |
| Quetiapine Fumarate | 92 | $1,449 |
| Duloxetine Hcl | 67 | $1,350 |
| Buspirone Hcl | 80 | $880 |
| Haloperidol Decanoate | 12 | $858 |
| Clonazepam | 110 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $149,486 | $218,19826 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17,949 | $33,35217 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $621 | $21,46325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Mobile
- Bradley SadlerMobile$124K
- Michael MarshallMobile$59K
- Mary Cohen ColsonMobile$10K
- Lucas BooneMobile$10K
- Bradley BrooksMobile$6K
- Sandra ParkerMobile$5K
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.